A Novel Mecp2
Animals
Behavior, Animal
Brain
/ metabolism
Chromatin
/ metabolism
Female
Gene Knock-In Techniques
Humans
Longevity
Male
Memory, Short-Term
Methyl-CpG-Binding Protein 2
/ metabolism
Mice
Mice, Inbred C57BL
Models, Biological
Mutation
/ genetics
Neurons
/ metabolism
Phenotype
Precision Medicine
Rett Syndrome
Chromatin accessibility
Chromatin binding
MeCP2
Mouse models
Rett syndrome
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
15
05
2018
accepted:
24
10
2018
pubmed:
8
11
2018
medline:
21
12
2019
entrez:
8
11
2018
Statut:
ppublish
Résumé
MeCP2 is a fundamental protein associated with several neurological disorders, including Rett syndrome. It is considered a multifunctional factor with a prominent role in regulating chromatin structure; however, a full comprehension of the consequences of its deficiency is still lacking. Here, we characterize a novel mouse model of Mecp2 bearing the human mutation Y120D, which is localized in the methyl-binding domain. As most models of Mecp2, the Mecp2
Identifiants
pubmed: 30402709
doi: 10.1007/s12035-018-1412-2
pii: 10.1007/s12035-018-1412-2
doi:
Substances chimiques
Chromatin
0
Methyl-CpG-Binding Protein 2
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4838-4854Subventions
Organisme : Fondazione Veronesi
ID : fellowship
Organisme : Fondazione Telethon
ID : GGP16015
Organisme : Italian Ministry of Research and Education
ID : RBFR10ZBYZ
Références
Amir RE, Van den Veyver IB, Wan M et al (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185–188. https://doi.org/10.1038/13810
doi: 10.1038/13810
pubmed: 10508514
Neul JL, Kaufmann WE, Glaze DG et al (2010) Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 68:944–950. https://doi.org/10.1002/ana.22124
doi: 10.1002/ana.22124
pubmed: 21154482
pmcid: 3058521
Baker SA, Chen L, Wilkins AD, Yu P, Lichtarge O, Zoghbi HY (2013) An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 152:984–996. https://doi.org/10.1016/j.cell.2013.01.038
doi: 10.1016/j.cell.2013.01.038
pubmed: 23452848
pmcid: 3641682
Bedogni F, Rossi RL, Galli F, Cobolli Gigli C, Gandaglia A, Kilstrup-Nielsen C, Landsberger N (2014) Rett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action. Neurosci Biobehav Rev 46:187–201. https://doi.org/10.1016/j.neubiorev.2014.01.011
doi: 10.1016/j.neubiorev.2014.01.011
pubmed: 24594195
Lyst MJ, Ekiert R, Ebert DH, Merusi C, Nowak J, Selfridge J, Guy J, Kastan NR et al (2013) Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci 16:898–902. https://doi.org/10.1038/nn.3434
doi: 10.1038/nn.3434
pubmed: 23770565
Nan X, Hou J, Maclean A, Nasir J, Lafuente MJ, Shu X, Kriaucionis S, Bird A (2007) Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc Natl Acad Sci 104:2709–2714. https://doi.org/10.1073/pnas.0608056104
doi: 10.1073/pnas.0608056104
pubmed: 17296936
Skene PJ, Illingworth RS, Webb S, Kerr ARW, James KD, Turner DJ, Andrews R, Bird AP (2010) Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell 37:457–468. https://doi.org/10.1016/j.molcel.2010.01.030
doi: 10.1016/j.molcel.2010.01.030
pubmed: 20188665
pmcid: 4338610
Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27:327–331. https://doi.org/10.1038/85906
doi: 10.1038/85906
pubmed: 11242118
Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27:322–326. https://doi.org/10.1038/85899
doi: 10.1038/85899
pubmed: 11242117
Ricceri L, De Filippis B, Laviola G (2008) Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav Pharmacol 19:501–517. https://doi.org/10.1097/FBP.0b013e32830c3645
doi: 10.1097/FBP.0b013e32830c3645
pubmed: 18690105
Stearns NA, Schaevitz LR, Bowling H, Nag N, Berger UV, Berger-Sweeney J (2007) Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome. Neuroscience 146:907–921. https://doi.org/10.1016/j.neuroscience.2007.02.009
doi: 10.1016/j.neuroscience.2007.02.009
pubmed: 17383101
Brown K, Selfridge J, Lagger S, Connelly J, de Sousa D, Kerr A, Webb S, Guy J et al (2016) The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome. Hum Mol Genet 25:558–570. https://doi.org/10.1093/hmg/ddv496
doi: 10.1093/hmg/ddv496
pubmed: 26647311
Bellini E, Pavesi G, Barbiero I, Bergo A, Chandola C, Nawaz MS, Rusconi L, Stefanelli G et al (2014) MeCP2 post-translational modifications: a mechanism to control its involvement in synaptic plasticity and homeostasis? Front Cell Neurosci 8:236. https://doi.org/10.3389/fncel.2014.00236
doi: 10.3389/fncel.2014.00236
pubmed: 25165434
pmcid: 4131190
Goffin D, Allen M, Zhang L, Amorim M, Wang ITJ, Reyes ARS, Mercado-Berton A, Ong C et al (2012) Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci 15:274–283. https://doi.org/10.1038/nn.2997
doi: 10.1038/nn.2997
D’Annessa I, Gandaglia A, Brivio E et al (2018) Tyr120Asp mutation alters domain flexibility and dynamics of MeCP2 DNA binding domain leading to impaired DNA interaction: atomistic characterization of a Rett syndrome causing mutation. Biochim Biophys Acta Gen Subj 1862:1180–1189. https://doi.org/10.1016/j.bbagen.2018.02.005
doi: 10.1016/j.bbagen.2018.02.005
pubmed: 29428602
Inui K, Akagi M, Ono J, Tsukamoto H, Shimono K, Mano T, Imai K, Yamada M et al (2001) Mutational analysis of MECP2 in Japanese patients with atypical Rett syndrome. Brain and Development 23:212–215. https://doi.org/10.1016/S0387-7604(01)00197-8
doi: 10.1016/S0387-7604(01)00197-8
pubmed: 11376998
Agarwal N, Becker A, Jost KL, Haase S, Thakur BK, Brero A, Hardt T, Kudo S et al (2011) MeCP2 Rett mutations affect large scale chromatin organization. Hum Mol Genet 20:4187–4195. https://doi.org/10.1093/hmg/ddr346
doi: 10.1093/hmg/ddr346
pubmed: 21831886
Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Schanen C, Tamura M (2003) Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J Med Genet 40:487–493. https://doi.org/10.1136/jmg.40.7.487
doi: 10.1136/jmg.40.7.487
pubmed: 12843318
pmcid: 1735522
Stefanelli G, Gandaglia A, Costa M, Cheema MS, di Marino D, Barbiero I, Kilstrup-Nielsen C, Ausió J et al (2016) Brain phosphorylation of MeCP2 at serine 164 is developmentally regulated and globally alters its chromatin association. Sci Rep 6:28295. https://doi.org/10.1038/srep28295
doi: 10.1038/srep28295
pubmed: 27323888
pmcid: 4915018
Bergo A, Strollo M, Gai M et al (2015) Methyl-CpG binding protein 2 (MeCP2) localizes at the centrosome and is required for proper mitotic spindle organization. J Biol Chem 290:3223–3237. https://doi.org/10.1074/jbc.M114.608125
doi: 10.1074/jbc.M114.608125
pubmed: 25527496
Cobolli Gigli C, Scaramuzza L, Gandaglia A, Bellini E, Gabaglio M, Parolaro D, Kilstrup-Nielsen C, Landsberger N et al (2016) MeCP2 related studies benefit from the use of CD1 as genetic background. PLoS One 11:e0153473. https://doi.org/10.1371/journal.pone.0153473
doi: 10.1371/journal.pone.0153473
pubmed: 27097329
pmcid: 4838291
Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143–1147. https://doi.org/10.1126/science.1138389
doi: 10.1126/science.1138389
pubmed: 17289941
Antonucci F, Corradini I, Morini R, Fossati G, Menna E, Pozzi D, Pacioni S, Verderio C et al (2013) Reduced SNAP-25 alters short-term plasticity at developing glutamatergic synapses. EMBO Rep 14:645–651. https://doi.org/10.1038/embor.2013.75
doi: 10.1038/embor.2013.75
pubmed: 23732542
pmcid: 3701242
Shahbazian MD, Young JI, Yuva-Paylor LA, Spencer CM, Antalffy BA, Noebels JL, Armstrong DL, Paylor R et al (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35:243–254. https://doi.org/10.1016/S0896-6273(02)00768-7
doi: 10.1016/S0896-6273(02)00768-7
pubmed: 12160743
Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L, Blue ME, Christian D et al (2012) Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech 5:733–745. https://doi.org/10.1242/dmm.011007
doi: 10.1242/dmm.011007
pubmed: 23115203
pmcid: 3484856
Bedogni F, Cobolli Gigli C, Pozzi D, Rossi RL, Scaramuzza L, Rossetti G, Pagani M, Kilstrup-Nielsen C et al (2016) Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms. Cereb Cortex 26:2517–2529. https://doi.org/10.1093/cercor/bhv078
doi: 10.1093/cercor/bhv078
pubmed: 25979088
Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Lovén J, Kwok SM, Feldman DA et al (2013) Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13:446–458. https://doi.org/10.1016/j.stem.2013.09.001
doi: 10.1016/j.stem.2013.09.001
pubmed: 24094325
pmcid: 4053296
Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, Calcagno E, Morello N et al (2011) Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 20:1182–1196. https://doi.org/10.1093/hmg/ddq563
doi: 10.1093/hmg/ddq563
pubmed: 21212100
Samaco RC, Fryer JD, Ren J, Fyffe S, Chao HT, Sun Y, Greer JJ, Zoghbi HY et al (2008) A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum Mol Genet 17:1718–1727. https://doi.org/10.1093/hmg/ddn062
doi: 10.1093/hmg/ddn062
pubmed: 18321864
pmcid: 2666042
Guy J, Cheval H, Selfridge J, Bird A (2011) The role of MeCP2 in the brain. Annu Rev Cell Dev Biol 27:631–652. https://doi.org/10.1146/annurev-cellbio-092910-154121
doi: 10.1146/annurev-cellbio-092910-154121
pubmed: 21721946
Kruusvee V, Lyst MJ, Taylor C, Tarnauskaitė Ž, Bird AP, Cook AG (2017) Structure of the MeCP2–TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders. Proc Natl Acad Sci 114:E3243–E3250. https://doi.org/10.1073/pnas.1700731114
doi: 10.1073/pnas.1700731114
pubmed: 28348241
Egloff S, Murphy S (2008) Role of the C-terminal domain of RNA polymerase II in expression of small nuclear RNA genes. Biochem Soc Trans 36:537–539. https://doi.org/10.1042/BST0360537
doi: 10.1042/BST0360537
pubmed: 18482001
Hirose Y, Ohkuma Y (2007) Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem 141:601–608. https://doi.org/10.1093/jb/mvm090
doi: 10.1093/jb/mvm090
pubmed: 17405796
Linhoff MW, Garg SK, Mandel G (2015) A high-resolution imaging approach to investigate chromatin architecture in complex tissues. Cell 163:246–255. https://doi.org/10.1016/j.cell.2015.09.002
doi: 10.1016/j.cell.2015.09.002
pubmed: 26406379
pmcid: 4583660
Phatnani HP, Greenleaf AL (2006) Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev 20:2922–2936. https://doi.org/10.1101/gad.1477006
doi: 10.1101/gad.1477006
pubmed: 17079683
Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, Lucero J, Huang Y et al (2013) Global epigenomic reconfiguration during mammalian brain development. Science 1237905–1237905:341. https://doi.org/10.1126/science.1237905
doi: 10.1126/science.1237905
Ludwig AK, Zhang P, Hastert FD, Meyer S, Rausch C, Herce HD, Müller U, Lehmkuhl A et al (2017) Binding of MBD proteins to DNA blocks Tet1 function thereby modulating transcriptional noise. Nucleic Acids Res 45:2438–2457. https://doi.org/10.1093/nar/gkw1197
doi: 10.1093/nar/gkw1197
pubmed: 27923996
Mellén M, Ayata P, Dewell S, Kriaucionis S, Heintz N (2012) MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151:1417–1430. https://doi.org/10.1016/j.cell.2012.11.022
doi: 10.1016/j.cell.2012.11.022
pubmed: 23260135
pmcid: 3653293
Lamonica JM, Kwon DY, Goffin D, Fenik P, Johnson BS, Cui Y, Guo H, Veasey S et al (2017) Elevating expression of MeCP2 T158M rescues DNA binding and Rett syndrome–like phenotypes. J Clin Invest 127:1889–1904. https://doi.org/10.1172/JCI90967
doi: 10.1172/JCI90967
pubmed: 28394263
pmcid: 5409785
Thambirajah AA, Eubanks JH, Ausió J (2009) MeCP2 post-translational regulation through PEST domains: two novel hypotheses. BioEssays 31:561–569. https://doi.org/10.1002/bies.200800220
doi: 10.1002/bies.200800220
pubmed: 19319913
Riedmann C, Fondufe-Mittendorf YN (2016) Comparative analysis of linker histone H1, MeCP2, and HMGD1 on nucleosome stability and target site accessibility. Sci Rep 6:33186. https://doi.org/10.1038/srep33186
doi: 10.1038/srep33186
pubmed: 27624769
pmcid: 5021983
Tillotson R, Selfridge J, Koerner MV, Gadalla KKE, Guy J, de Sousa D, Hector RD, Cobb SR et al (2017) Radically truncated MeCP2 rescues Rett syndrome-like neurological defects. Nature 550:398–401. https://doi.org/10.1038/nature24058
doi: 10.1038/nature24058
pubmed: 29019980
pmcid: 5884422